Related Experiment Video

Updated: Jul 10, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents

Jack M Sullivan1, Edwin H Yau, R Thomas Taggart

  • 1Department of Ophthalmology, SUNY, University at Buffalo, Veterans Administration Western New York Healthcare System, Medical Research, Building 20, Room 245, 3495 Bailey Avenue, Buffalo, NY 14215, USA. jackmsullivanmdphd@yahoo.com

Vision Research
|November 3, 2007
PubMed

Insights

Developing post-transcriptional gene silencing (PTGS) agents for therapy faces challenges due to complex target RNA structures. This review explores bottlenecks and emerging technologies to overcome these limitations for gene-based therapies.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Biochemistry

Background:

  • Post-transcriptional gene silencing (PTGS) agents are crucial for targeted RNA and protein knockdown.
  • Established PTGS technologies like antisense, ribozyme, and RNAi rely on ligand-target RNA annealing.

Purpose of the Study:

  • To review the challenges and bottlenecks in developing PTGS agents for therapeutic applications.
  • To highlight the impact of target RNA structural complexity on PTGS efficacy.
  • To explore emerging technologies that address these limitations.

Main Methods:

  • Literature review of existing and novel PTGS technologies.
  • Analysis of biocomplexity in target RNA structures.
  • Discussion of constraints limiting therapeutic PTGS development.

Main Results:

  • The annealing step of PTGS ligands to target RNA is a critical bottleneck.
  • Target RNA structural complexity significantly hinders PTGS agent efficiency.
  • Various existing and emerging technologies aim to overcome these annealing and structural constraints.

Conclusions:

  • Realizing the therapeutic potential of PTGS agents requires overcoming significant biological hurdles.
  • Emerging technologies show promise in enhancing PTGS agent efficacy for gene-based therapies.
  • Addressing target RNA structural complexity is key to advancing PTGS therapeutics.

More Related Videos

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...